Nurix Therapeutics climbs after blood cancer drug trial data
08/12/2025 14:07
** Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket ** NRIX said 75% of patients demonstrated objective response rate in early-stage trial for blood cancer drug Bexobrutideg (NX-5948), with mostly mild side effects ** Drug is aimed at degrading BTK, a protein that drives the disease ** NRIX set to open at its highest after a year if current gains hold ** Stock down nearly 4% YTD, up to last close (Reporting by Utkarsh Tushar Hathi) ((utkarshtushar.hathi@thomsonreuters.com))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis